Expert Review of Anti-infective Therapy最新文献_第2页

Building upon the core elements of antifungal stewardship: practical recommendations for effective antifungal stewardship in resource-limited settings.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-12 DOI: 10.1080/14787210.2025.2479011

Arunaloke Chakrabarti, Rita Oladele, Elizabeth Hermsen, Maria Lavinea Novis de Figueiredo, Patricia Muñoz, Melissa Johnson

{"title":"Building upon the core elements of antifungal stewardship: practical recommendations for effective antifungal stewardship in resource-limited settings.","authors":"Arunaloke Chakrabarti, Rita Oladele, Elizabeth Hermsen, Maria Lavinea Novis de Figueiredo, Patricia Muñoz, Melissa Johnson","doi":"10.1080/14787210.2025.2479011","DOIUrl":"https://doi.org/10.1080/14787210.2025.2479011","url":null,"abstract":"Introduction: Despite the crucial importance of effective AFS in resource-limited settings, such settings remain comparatively underserved and underrepresented in terms of resource-setting-specific guidance and research. Further practical contextualization and application of current AFS best practices is thus necessary.Areas covered: A panel of leading experts from diverse countries (India, Nigeria, Spain, and the US) was brought together to provide recommendations for practical and effective implementation of AFS in resource-limited settings. We have adapted and contextualized the Centers for Disease Control and Prevention's (CDC) seven core elements and the Mycoses Study Group Education and Research Consortium's (MSGERC) recommendations for facilities in resource-limited settings through a resource-stratified approach. Where relevant to facilities based on their context and respective resources across multiple dimensions, facilities may choose to prioritize certain recommendations that may be more immediately actionable before implementing others.Expert opinion: We recommend future studies to examine the efficacy, cost-effectiveness, and practicality of our recommendationsin resource-limited settings to enable them to effectively prioritize, channel or gradually increase resource capacity at hand. AFS interventions should be integrated within a larger systemic framework (e.g. city, state, national, regional, international) with collaboration among institutional leadership, ID specialists, healthcare workers, public, policymakers, and pharmaceutical industry.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrence of group B streptococcal infections in infants: a systematic review.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-10 DOI: 10.1080/14787210.2025.2474569

Francesca Miselli, Alessandra Boncompagni, Riccardo Cuoghi Costantini, Tommaso Zini, Luca Bedetti, Martina Buttera, Lucia Corso, Roberta Creti, Isotta Guidotti, Cecilia Rossi, Eugenio Spaggiari, Licia Lugli, Alberto Berardi

{"title":"Recurrence of group B streptococcal infections in infants: a systematic review.","authors":"Francesca Miselli, Alessandra Boncompagni, Riccardo Cuoghi Costantini, Tommaso Zini, Luca Bedetti, Martina Buttera, Lucia Corso, Roberta Creti, Isotta Guidotti, Cecilia Rossi, Eugenio Spaggiari, Licia Lugli, Alberto Berardi","doi":"10.1080/14787210.2025.2474569","DOIUrl":"https://doi.org/10.1080/14787210.2025.2474569","url":null,"abstract":"Introduction: Group-B Streptococcus(GBS) infections may rarely recur after antibiotic treatment. We aimed to fill existing gaps on epidemiology, clinical features, and outcomes of GBS recurrences.Methods: A systematic search of PubMed and Embase was conducted, covering the period until 1 July 2024. The demographics, clinical characteristics, treatment, and outcomes of infants withGBS recurrence were analyzed. Recurrence was defined as > 1 episode of invasiveGBS infection (positive blood and/or cerebrospinal fluid culture), occurring after the completion of treatment for the initial episode.Results: Among the 213 recurrences, 146 reported individual data and were included in the analysis. GBS recurrences developed shortly after the completion of antibiotic treatment for the initial infection (median = 10 days 95%CI 6.0-18.8). Most infants were preterm (63.5%) and had received an adequately long course of antibiotics for the initial infection (median = 13 days, 95%CI 10-14). Serotype III waspredominant. Breast milk yielded GBS in most samples cultured (41/62, 66%); 5/15 (33%) infants who discontinued breastfeeding after recurrence had further GBS recurrence. Case fatalities were 3.7%.Conclusions: Preterm birth is closely associated with GBS recurrences. Adequately long courses of antibiotics or withdrawal of breast milk may not be useful measures to prevent recurrences.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":4.2,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The ongoing challenge of prevention of pertussis in infants: what's new in 2024?

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-09 DOI: 10.1080/14787210.2025.2476010

Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola

{"title":"The ongoing challenge of prevention of pertussis in infants: what's new in 2024?","authors":"Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola","doi":"10.1080/14787210.2025.2476010","DOIUrl":"10.1080/14787210.2025.2476010","url":null,"abstract":"Introduction: Pertussis, a respiratory disease caused primarily by Bordetella pertussis, is undergoing a resurgence despite decades of high rates of vaccination. The prevention of pertussis in infants presents several challenges, including the waning immunity of the acellular pertussis (aP) vaccine, the limited protection afforded to newborns before they complete the vaccine series, and the existence of gaps in maternal vaccination. Furthermore, the unwillingness or refusal of a considerable number of individuals, including some healthcare workers, to receive vaccinations represents another significant challenge.Areas covered: This narrative review provides an updated overview of the ongoing challenge of preventing pertussis in infants and discusses some possible solutions.Expert opinion: The ongoing challenge of preventing pertussis in infants is multifaceted. To address these challenging issues, a multi-pronged approach is required. This approach should be designed to address various barriers and increase uptake. It should include measures to strengthen maternal vaccination programs, ensure timely infant vaccinations, improve public education, and continue research into more effective vaccines with longer-lasting immunity.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":4.2,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-04 DOI: 10.1080/14787210.2025.2473044

Daniele Focosi, David J Sullivan, Massimo Franchini

引用次数: 0

Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-04 DOI: 10.1080/14787210.2025.2473077

Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione

{"title":"Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.","authors":"Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione","doi":"10.1080/14787210.2025.2473077","DOIUrl":"10.1080/14787210.2025.2473077","url":null,"abstract":"Introduction: Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety and efficacy in the short term; however, prolonged course of antibiotics has been documented in multiple clinical settings. The aim of this narrative review is to provide a new perspective on SAT and to discuss new therapeuticpossibilities.Areas covered: We discuss new clinical scenarios in which SAT could be considered. We provided a broad discussion about long-acting agents and new or repurposed oral agents as well as the use of OPAT with elastomeric pumps and an overview of the pipeline of new antifungals. Limitations of SAT are presented in this review and especially patients' adherence issues, possible spread of MDROs, possible rising of the incidence of Clostridioides difficile infections, drug-to-drug interactions and drug-related problems, cost-effectiveness evaluation issues.Expert opinion: Many research gaps are evident and further studies are needed. Above all, the efficacy and safety of SAT in the different clinical scenarios. Discovery of new molecules against MDROs and ongoing research on PK/PD variables as well as a better understanding of the relationship between SAT and the emergence of resistance could improve SAT usage and reduce the impact of DRPs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Past, present, and future perspectives on aztreonam and avibactam.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-04 DOI: 10.1080/14787210.2025.2473047

Karen Bush

{"title":"Past, present, and future perspectives on aztreonam and avibactam.","authors":"Karen Bush","doi":"10.1080/14787210.2025.2473047","DOIUrl":"10.1080/14787210.2025.2473047","url":null,"abstract":"Introduction: Aztreonam is a monobactam antibiotic approved in 1986 to treat infections caused by aerobic Gram-negative bacteria, but, together with cephalosporins, lost clinical utility due to the emergence of extended-spectrum β-lactamases (ESBLs) and novel (serine) carbapenemases. Avibactam was the first in a novel non-β-lactam β-lactamase inhibitor class to effectively inhibit these enzymes. It has been approved in combination with ceftazidime to treat Gram-negative infections caused by bacteria that produce AmpC, ESBLs and serine carbapenemases, and with aztreonam to treat patients infected with metallo-β-lactamase-producing enteric bacteria. Combinations of avibactam with ceftazidime and/or aztreonam have been used successfully to treat enteric pathogens producing multiple classes of β-lactamases.Areas covered: Development of aztreonam, avibactam, and avibactam combinations are placed into a historical perspective, based on both preclinical and clinical data. A search of MEDLINE (Ovid) was used to identify relevant literature.Expert opinion: Avibactam combined with ceftazidime and aztreonam in either dual or triple combinations provides the opportunity to treat previously untreatable Gram-negative infections that produce multiple β-lactamases. Aztreonam combinations should be particularly attractive, due to stability to metallo-β-lactamase hydrolysis and its safety advantage in treating penicillin-allergic patients. Other inhibitor combinations in development may challenge these combinations.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":4.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-26 DOI: 10.1080/14787210.2025.2472346

Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin

{"title":"Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.","authors":"Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin","doi":"10.1080/14787210.2025.2472346","DOIUrl":"10.1080/14787210.2025.2472346","url":null,"abstract":"Background: High-dose (HD) tigecycline is often required for severe multidrug-resistant gram-negative infections in liver failure patients, despite package recommendations to halve the dose for those with severe liver impairment. This study evaluated the efficacy and safety of different tigecycline doses in this population.Research design and methods: A retrospective cohort of 192 patients with Child-Pugh grade C liver failure was divided into label-dose (LD), standard-dose (SD), and HD groups. Primary and secondary outcomes included microbial eradication, mortality, and adverse effects.Results: The SD group achieved higher microbial eradication than LD, with comparable efficacy to HD but fewer adverse events, such as fibrinogen requirements. High-dose treatment increased mortality risk (Hazard Ratio: 1.85, p = 0.062). Optimal microbial eradication and minimized adverse effects occurred with the SD group at 7 days of treatment.Conclusions: Standard-dose tigecycline offers a balanced approach to microbial eradication and safety, making it preferable in liver failure patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":4.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'Real-life' approach to applying PK/PD principles in infectious diseases clinical practice without access to prompt TDM. 在没有及时TDM的情况下，在传染病临床实践中应用PK/PD原则的“现实生活”方法。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1080/14787210.2024.2448727

Nicholas Geremia, Stefano Di Bella, Antonio Lovecchio, Jacopo Angelini, Antonio D'Avolio, Roberto Luzzati, Filippo Mearelli, Luigi Principe, Alessandra Oliva

{"title":"'Real-life' approach to applying PK/PD principles in infectious diseases clinical practice without access to prompt TDM.","authors":"Nicholas Geremia, Stefano Di Bella, Antonio Lovecchio, Jacopo Angelini, Antonio D'Avolio, Roberto Luzzati, Filippo Mearelli, Luigi Principe, Alessandra Oliva","doi":"10.1080/14787210.2024.2448727","DOIUrl":"10.1080/14787210.2024.2448727","url":null,"abstract":"Introduction: Infectious disease treatments are transitioning from a one-size-fits-all approach to a more tailored approach. The increasing adoption of therapeutic drug monitoring (TDM) of antimicrobials is a clear example of this trend. Routine antimicrobial TDM in critically ill patients should be mandatory. Unfortunately, nowadays, only expert centers can provide it. Given the crucial nature of the first hours/days for achieving a favorable clinical outcome, empirical antibiotic therapy with an adequate choice of drug, dose and administration modalities is fundamental.Areas covered: We outline common scenarios encountered in clinical practice, such as in edematous patients, hypoalbuminemia, patients with liver and renal diseases, patients under renal replacement therapy or extracorporeal membrane oxygenation (ECMO), over or under-weight patients, in old adults and cases of infections caused by relatively high minimum inhibitory concentration (MIC) pathogens. Various clinical situations were analyzed with the help of the available literature (PubMed/MEDLINE/Google Scholar and books written by experts in pharmacology and infectious diseases).Expert opinion: In these different scenarios, we reported common examples of optimizing drug utilization to maximize therapeutic outcomes, reduce incorrect prescriptions and limit the emergence of antimicrobial resistance.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"119-134"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-leishmanial therapies: overcoming current challenges with emerging therapies. 抗利什曼疗法：用新兴疗法克服当前的挑战。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-03-24 DOI: 10.1080/14787210.2024.2438627

Shyam Sundar, Prasoon Madhukar, Rajiv Kumar

{"title":"Anti-leishmanial therapies: overcoming current challenges with emerging therapies.","authors":"Shyam Sundar, Prasoon Madhukar, Rajiv Kumar","doi":"10.1080/14787210.2024.2438627","DOIUrl":"10.1080/14787210.2024.2438627","url":null,"abstract":"Introduction: Leishmaniasis, including visceral, cutaneous, and mucocutaneous forms, present a major health challenge in tropical regions. Current antileishmanial medications has significant limitations, creating a critical need for novel therapies that are safe and cost-effective with a shorter duration of treatment.Areas covered: This review explores the critical aspects of existing antileishmanial therapy and targets for future therapeutic developments. It emphasizes the need for new treatment options due to drug resistance, low success rates, toxicity, and high prices associated with current medications. The different forms of leishmaniasis, their clinical manifestations, the challenges associated with their treatment and emerging treatment options are explored in detail.Expert opinion: The first anti-leishmanial drug pentavalent antimony (SbV) was invented more than 100 years back. Since then, this compound has been used for all forms of leishmaniasis worldwide. For more than 70-80 years after discovery of SbV, no new antileishmanial drugs were developed, reflecting the lack of interest from academia or pharma industry. All three new treatments (Amphotericin-B, paromomycin and miltefosine) which underwent the clinical trials were repurposed drugs. The current pipeline for antileishmanial drugs is empty, with LXE 408 being the only potential drug reaching phase II clinical trial.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"159-180"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on newer antifungals.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-02-04 DOI: 10.1080/14787210.2025.2461566

Karolina Akinosoglou, Despoina Papageorgiou, Charalambos Gogos, George Dimopoulos

引用次数: 0